BTIG Research Reports Initiation of Akebia Therapeutics (NDAQ:AKBA) with $30.00 Target; Profile of 2 Analysts Covering Independent Oil and Gas plc (LON:IOG)

December 7, 2017 - By Vivian Currie

Among 2 analysts covering Independent Oil Gas PLC (LON:IOG), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Independent Oil Gas PLC had 58 analyst reports since August 13, 2015 according to SRatingsIntel. FinnCap maintained the shares of IOG in report on Friday, September 30 with “Corporate” rating. FinnCap maintained the shares of IOG in report on Wednesday, September 30 with “Corporate” rating. The stock has “Corporate” rating by FinnCap on Thursday, July 14. FinnCap maintained the shares of IOG in report on Tuesday, April 11 with “Corporate” rating. The firm has “Corporate” rating by FinnCap given on Tuesday, March 21. The stock has “Corporate” rating by FinnCap on Friday, July 29. The firm has “Corporate” rating by FinnCap given on Friday, August 19. The rating was maintained by FinnCap with “Corporate” on Wednesday, January 13. The rating was maintained by VSA Capital with “Buy” on Wednesday, September 13. FinnCap maintained it with “Corporate” rating and GBX 123 target in Tuesday, October 31 report. See Independent Oil and Gas plc (LON:IOG) latest ratings:

29/11/2017 Broker: FinnCap Rating: Corporate Old Target: GBX 123.00 New Target: GBX 123.00 Maintain
10/11/2017 Broker: VSA Capital Rating: Buy Maintain
10/11/2017 Broker: FinnCap Rating: Corporate Old Target: GBX 123.00 New Target: GBX 123.00 Maintain
02/11/2017 Broker: FinnCap Rating: Corporate Old Target: GBX 123.00 New Target: GBX 123.00 Maintain
01/11/2017 Broker: VSA Capital Rating: Buy Maintain
31/10/2017 Broker: FinnCap Rating: Corporate Old Target: GBX 123.00 New Target: GBX 123.00 Maintain
18/10/2017 Broker: VSA Capital Rating: Buy Maintain
18/10/2017 Broker: FinnCap Rating: Corporate Old Target: GBX 123.00 New Target: GBX 123.00 Maintain
12/10/2017 Broker: VSA Capital Rating: Buy Maintain
12/10/2017 Broker: FinnCap Rating: Corporate Old Target: GBX 123.00 New Target: GBX 123.00 Maintain

Among 4 analysts covering Akebia Therapeutics Inc (NDAQ:AKBA), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Akebia Therapeutics Inc has $25 highest and $17 lowest target. $21’s average target is 36.36% above currents $15.4 stock price. Akebia Therapeutics Inc had 6 analyst reports since March 27, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, April 27 by Needham. The stock has “Buy” rating by Aegis Capital on Monday, March 27. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, April 27 report. On Friday, September 15 the stock rating was initiated by RBC Capital Markets with “Sector Perform”. The company was maintained on Monday, July 10 by H.C. Wainwright.

The stock increased 1.38% or $0.21 during the last trading session, reaching $15.4. About 225,692 shares traded. Akebia Therapeutics, Inc. (NDAQ:AKBA) has risen 76.80% since December 7, 2016 and is uptrending. It has outperformed by 60.10% the S&P500.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology. The company has market cap of $727.95 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. It currently has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

Investors sentiment increased to 2.25 in 2017 Q2. Its up 1.17, from 1.08 in 2017Q1. It is positive, as 10 investors sold Akebia Therapeutics, Inc. shares while 22 reduced holdings. 38 funds opened positions while 34 raised stakes. 26.05 million shares or 30.12% more from 20.02 million shares in 2017Q1 were reported. Citigroup stated it has 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Spark Limited Liability Corp has invested 0.03% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Foresite Capital Ii Ltd Limited Liability Company has invested 0.33% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Ameriprise Financial holds 0% or 84,655 shares. Point72 Asia (Hong Kong) Limited holds 3,828 shares or 0.06% of its portfolio. Panagora Asset Mngmt holds 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA) or 30,126 shares. Alyeska Group L P has invested 0.02% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Amer Intll Group Inc Inc reported 22,884 shares. Jacobs Levy Equity reported 19,480 shares stake. Mcf Advsr Lc holds 0% or 913 shares in its portfolio. 31 are held by Cwm Limited Liability Corporation. Moreover, Royal Financial Bank Of Canada has 0% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Deutsche Bankshares Ag accumulated 275,191 shares. Sg Americas Ltd Co invested in 9,184 shares. Opus Point Prns Limited Liability Corporation reported 21,009 shares.

Analysts await Akebia Therapeutics, Inc. (NASDAQ:AKBA) to report earnings on March, 5. They expect $-0.53 EPS, up 46.46% or $0.46 from last year’s $-0.99 per share. After $-0.49 actual EPS reported by Akebia Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 8.16% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com